• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Dabigatran (Pradaxa).达比加群（普伐他汀）。
AJNR Am J Neuroradiol. 2012 Mar;33(3):426-8. doi: 10.3174/ajnr.A3000. Epub 2012 Feb 16.
2
[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].[华法林与达比加群酯治疗静脉血栓栓塞症的利弊]
Vestn Khir Im I I Grek. 2014;173(4):87-91.
3
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.达比加群（Pradaxa）：用于治疗深静脉血栓形成和肺栓塞。华法林仍是标准用药。
Prescrire Int. 2015 Jun;24(161):150.
4
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.抗凝治疗的选择——为何美国食品药品监督管理局批准了达比加群的较高剂量而非较低剂量。
N Engl J Med. 2011 May 12;364(19):1788-90. doi: 10.1056/NEJMp1103050. Epub 2011 Apr 13.
5
Avoiding adverse events with dabigatran by careful selection of eligible patients.通过仔细挑选合适的患者来避免达比加群的不良事件。
Med J Aust. 2012 Apr 16;196(7):431-2. doi: 10.5694/mja11.11268.
6
Dabigatran in patients with nonvalvular atrial fibrillation.达比加群用于非瓣膜性心房颤动患者
J Am Coll Cardiol. 2011 Jul 26;58(5):551; author reply 551. doi: 10.1016/j.jacc.2011.04.016.
7
[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].达比加群酯：用于预防非瓣膜性心房颤动患者中风的新型抗凝剂
Kardiologiia. 2011;51(11):83-90.
8
[Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].[老年非瓣膜性心房颤动患者三种抗栓治疗方法的比较]
Kardiologiia. 2012;52(7):56-60.
9
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.达比加群、利伐沙班和阿哌沙班所致出血的实用处理方法。
Cleve Clin J Med. 2013 Jul;80(7):443-51. doi: 10.3949/ccjm.80a.13025.
10
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.老年 Medicare 患者在非瓣膜性心房颤动中接受达比加群或华法林治疗的心血管、出血和死亡率风险。
Circulation. 2015 Jan 13;131(2):157-64. doi: 10.1161/CIRCULATIONAHA.114.012061. Epub 2014 Oct 30.

引用本文的文献

1
Antithrombotic prophylaxis following total knee arthroplasty: a level I Bayesian network meta-analysis.全膝关节置换术后抗血栓预防：Ⅰ级贝叶斯网络荟萃分析。
Eur J Orthop Surg Traumatol. 2024 Aug;34(6):2881-2890. doi: 10.1007/s00590-024-04071-w. Epub 2024 Aug 10.
2
Incidence and Prognostic Factors of Radial Artery Occlusion in Transradial Coronary Catheterization.经桡动脉冠状动脉介入治疗中桡动脉闭塞的发生率及预后因素
J Clin Med. 2024 Jun 1;13(11):3276. doi: 10.3390/jcm13113276.
3
Antithrombotic prophylaxis following total hip arthroplasty: a level I Bayesian network meta-analysis.全髋关节置换术后抗血栓预防：I 级贝叶斯网络荟萃分析。
J Orthop Traumatol. 2024 Jan 9;25(1):1. doi: 10.1186/s10195-023-00742-2.
4
Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition.活化的凝血因子X（FXa）通过促进视网膜色素上皮（RPE）上皮-间质转化，促进外伤性增殖性玻璃体视网膜病变（PVR）的发展。
Invest Ophthalmol Vis Sci. 2021 Jul 1;62(9):29. doi: 10.1167/iovs.62.9.29.
5
Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet.使用检查表对直接口服抗凝剂处方审核系统进行改进与评估。
J Pharm Health Care Sci. 2021 Jun 1;7(1):22. doi: 10.1186/s40780-021-00205-y.
6
Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions.利用直接口服抗凝剂的药物遗传学预测其药代动力学变化及药物不良反应风险。
Biomedicines. 2021 Apr 22;9(5):451. doi: 10.3390/biomedicines9050451.
7
Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations.达比加群监测受不同浓度凝血酶试剂的影响。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619867137. doi: 10.1177/1076029619867137.

本文引用的文献

1
Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.口服直接凝血酶抑制剂达比加群抗凝治疗不会增加实验性脑出血的血肿体积。
Circulation. 2011 Oct 11;124(15):1654-62. doi: 10.1161/CIRCULATIONAHA.111.035972. Epub 2011 Sep 12.
2
Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation.心房颤动患者预防中风的药物治疗策略。
Curr Treat Options Cardiovasc Med. 2011 Oct;13(5):361-9. doi: 10.1007/s11936-011-0139-4.
3
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.达比加群酯与华法林预防房颤卒中的成本效果比较。
Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.
4
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.达比加群酯——一种新型、可逆、口服直接凝血酶抑制剂：凝血检测的解读及其抗凝活性的逆转。
Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29.
5
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.肾功能损害对口服达比加群酯的药代动力学和药效学的影响：一项开放标签、平行组、单中心研究。
Clin Pharmacokinet. 2010 Apr;49(4):259-68. doi: 10.2165/11318170-000000000-00000.
6
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.达比加群通过依赖于和不依赖于凝血酶激活的纤溶抑制物的机制增强血栓对纤溶的敏感性。
J Thromb Haemost. 2010 Apr;8(4):790-8. doi: 10.1111/j.1538-7836.2010.03739.x. Epub 2010 Jan 17.
7
Dabigatran versus warfarin in patients with atrial fibrillation.达比加群与华法林用于房颤患者的比较。
N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
8
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.口服直接凝血酶抑制剂和Xa因子抑制剂在研的比较药效学和药代动力学
Clin Pharmacokinet. 2009;48(1):1-22. doi: 10.2165/0003088-200948010-00001.
9
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.直接口服凝血酶抑制剂达比加群在健康老年受试者中的药代动力学和药效学
Clin Pharmacokinet. 2008;47(1):47-59. doi: 10.2165/00003088-200847010-00005.
10
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.新型口服直接凝血酶抑制剂达比加群酯在健康男性受试者中的药代动力学、药效学及耐受性
Br J Clin Pharmacol. 2007 Sep;64(3):292-303. doi: 10.1111/j.1365-2125.2007.02899.x. Epub 2007 May 15.

达比加群（普伐他汀）。

Dabigatran (Pradaxa).

机构信息

St Vincent's Hospital, Melbourne, Australia.

出版信息

AJNR Am J Neuroradiol. 2012 Mar;33(3):426-8. doi: 10.3174/ajnr.A3000. Epub 2012 Feb 16.

DOI:10.3174/ajnr.A3000
PMID:22345499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7966436/
Abstract

Dabigatran (Pradaxa) is a member of the relatively new class of antithrombotic drugs known as direct thrombin inhibitors (DTIs). It may supplant warfarin (Coumadin) in a number of applications as it may produce a more predictable, potent, and immediate anticoagulant effect, with fewer significant side effects and interactions, and requires less monitoring.

摘要

达比加群（普伐他汀）是一种新型抗血栓药物，属于直接凝血酶抑制剂（DTIs）。它可能会在许多应用中替代华法林（Coumadin），因为它可能产生更可预测、更有效和更直接的抗凝作用，副作用和相互作用更少，监测需求也更少。